Recursion Pharmaceuticals Inc (RXRX) Options

Pharma on the verge of merger/acquisition.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175821245

Cross road,

can RXRX - star get realignment with ,,,, - asking NVDA's AI brain & Cathy's unknown brain

Noted. You are so kind

Hopelessly overvalued, overhyped AI stuff.
ZERO approved products
If this drops to $3, it could still be over-valued

dark green like black

Big volume -- could be green EOD

once cross 36 - it is open sky.
everyday dips are the advantage point
buying the $200 -$300 /sh stock of 2025 at $11 -$36

could move $3 -$5 today

https://x.com/RecursionChris/status/1747265218437349847

I'd wager that undisclosed information is at play, but that wouldn't be legal, so couldn't possibly be the case.

So why do you think it keeps going higher! 

blindfold buy at 20 - 30 then the jump 100 - 200

RXRX

They announce a mixed shelf (dilution), and the price spikes?

RXRX just started little little sprinting step before planting the pole and jump over that record high pole vault bar

invest - - soon --- before out of reach.

this is a stock will gain 200-300% in a single day-- but today - no - it will go back to +3c or -3c in 1h

This level of result, will make this company fly:

https://www.globenewswire.com/news-release/2025/02/05/3021646/0/en/Recursion-Presents-Phase-2-Data-for-REC-994-in-CCM-in-Late-Breaking-Oral-Presentation-at-the-International-Stroke-Conference.html

generative AI in making medical miracle

REC-994 MRI-based brainstem lesion volume reduction : place a $M maker brick now

70 institution 30 public--that's how RXRX drug working now

YouTube influencer position - write or call cGibson@recursion.com

Exactly, when we see the lending fees start to rise, then I will buy more. Brokers always make money, even when investors lose.

they all do etard fidal TDA, but that gives the opportunity to buy low. This RxRx defines the future of MED world in AI stage- just buying little little within affordability. definitively it will grow like MSTF GOOG AAPL NVDA AMZN.., All drug lords pfizer, j&j eli, merck roche AZ BMS are lining up behind, just give few months to a year for first $100

Fidelity is loaning shares to shorts.

next piece of clinical update will take it above 20 and after that it is in different league.

Sure looks like early days of ISRG ILMN,

Nvidia invested $50M in this company. ARK is a holder. This will be huge, once their first find gets FDA approval, and proof of concept is secured.

interesting no posters in this
future $200 - $300 stock, and that future not far - see the quality of clinical data, target diseases, and the time it took to reach there - not standard 20 ys but 3y to ph3 and a large advancing failure resistant AI powered pipeline

change of heart -going up.

rxrx WORLD

promised to accumulate 10k shares before Q end and hold for years. predict this issue never go BK, do RS, and one day go beyond 200+ like established big cap security issues.

bandwagon

believe in miracle ----- come to RXRX------

Looks like Lilly is late to the party.

https://www.statnews.com/2025/01/10/eli-lilly-andreessen-horowitz-500-million-venture-fund-ai-focus/

cursion-re-cursion in flame after FDA REC 3565 blessings

Gibson🤢🥵🥶😷Gibson

baby nvda

balding haircut at RXRX

RXRX, under $7

out for now, let CEO work his magic if he has one under his sleeve

is something wrong with RxRx, it looked promising based on what said to public. but something not right. ground shaken up. - like trouble.
what wrong with the CEO. if this continues that is bad sign for future of the company and the CEO.

RXRX

RxRx partnership: GOOG NVDA MSFT Roche/Genentech Bayer Bristol Myers Squibb Sanofi Merck ......

RxRx M&A: Valence –Cyclica - Exscientia
Valence – a leader in generative AI and deep learning models
Cyclica - a deep learning engine that predicts the polypharmacology of small molecules in drug discovery.
Exscientia - AI-driven precision medicine
RXRX - Regenerative AI - TechBio powerhouse
undergoing post merger reorganization, some job cuts
enough cash to fund through 2027
Ark Q3 2024 Stake: $215.9 million
Hedge Fund Investors Q3 2024:: 16
more than ten drugs in trials.

market up big and RxRx ignored,
if quantum computing which is 7-10 years away getting attention now, then this should be in the rocket heading for stratosphere.

RXRX seeing some promising results in early trials. Proof of concept will solidify belief in the platform.

If cost of trials can be reduced, by less attrition of candidates, then they should see more licensing agreements, and funding, from pharma companies IMO.

Revenue (ttm) 65.18M; Quarterly Revenue Growth (yoy) 147.60%
Total Cash (mrq) 427.65M; Total Debt (mrq) 90.62M
Shares Outstanding 6 388.94M; Float 8 252.42M
clinical trial : REC-994 in Phase 2, REC-2282 in Phase 2/3; few other in phase 1 and 2, all in less than 2 year not 15-18 years (conventional).

% Held by Institutions 1 69.40% Shares Short (Nov 15, 2024) 4 64.57M 25%

Rxrx share price Long Tail Up since 06 Dec 2024.